BRAF Biomarkers News and reporting on BRAF biomarkers. Kinnate Biopharma, Guardant Health Partner for Study of BRAF Mutations in Solid Tumors Preliminary findings indicate that about half of the 6,000 patients with BRAF alteration-positive cancers harbored Class II and III alterations. MapKure, Personalis Partner to Screen Patients for BRAF Inhibitor Trial Personalis plans to develop a companion diagnostic to MapKure's BRAF inhibitor, BGB-3245, once biomarkers have been identified in the study. Novellus, Tempus Partner to Enroll Patients in BRAF Inhibitor Clinical Trial Program The Jerusalem-based drug developer is studying PLX8394 in patients with BRAF V600-mutated gliomas and solid tumors with non-V600 mutations. Melanoma Treatment Stage Affects Ability of Liquid Biopsy to Predict Immunotherapy Benefit Premium Researchers showed that ctDNA levels predicted who would respond to first-line immune checkpoint inhibition but were not useful in second-line therapy. Strata Oncology, BioMed Valley Discoveries Partner on Patient Enrollment for Ulixertinib Study Through the partnership, Strata will use its next-generation sequencing test to identify advanced cancer patients with mutations in the MAPK signaling pathway. Apr 27, 2020 Amid COVID-19, Lower Cancer Diagnosis Rates Mean Fewer Patients Getting Molecular Tests, Treatment Premium Feb 13, 2020 Genetron Health Obtains Regulatory Approval in China for NGS Instrument, Lung Cancer Panel Jan 27, 2020 Colon Cancer Biomarker Undertesting Rates in Real-World Data Points to Precision Oncology Barriers Premium Sep 23, 2019 Global Survey Reveals Suboptimal Molecular Testing Access in Lung Cancer Despite Broad Guidelines Premium Jun 18, 2019 Next-Generation Sequencing of Pediatric Cancer Patients Could Transform Treatment Paradigms Premium Jun 6, 2019 TAPUR Study Investigators Report First Positive Findings, Pursuing Tissue-Agnostic Cohorts Premium May 16, 2019 NCI Pediatric MATCH Trial Interim Data Shows 24 Percent of Patients Eligible for Targeted Therapy Premium May 9, 2019 Liquid Biopsy of Melanoma Surgery Drainage Fluid Shows Promise for Recurrence Monitoring Premium Jan 25, 2019 MethylDetect Looks to Leverage High-Resolution Melt Tech for Oncology Assay Development Premium Jan 10, 2019 Melanoma BRAF Mutation Type May Affect Response to Targeted Treatments, Immunotherapy Aug 7, 2018 Researchers Integrate Genotyping Assay, Drug Delivery Tech for Precision Glioma Treatment Premium Jun 18, 2018 Recurrent Rearrangements Identified in Rare Infant Soft Tissue Tumors May 31, 2018 PanDrugs System Aims to Advance Precision Cancer Care by Matching Treatments to Mutations Premium Nov 6, 2017 Genentech's Zelboraf Gets FDA Approval in BRAF Mutation-Positive Erdheim-Chester Disease Jun 22, 2017 Thermo Fisher Next-Gen Sequencing Panel Wins FDA Approval as Companion Test Jun 22, 2017 Quest Diagnostics to Expand Advanced Cancer Care to Community Oncologists Through Recent Acquisitions Premium May 1, 2017 BRAF Proficiency Testing Reporting Adequate But Could Improve, Analysis Finds Feb 16, 2017 Head-to-Head Comparison of BRAF Assays Yields Clues About Ideal Use in Guiding Melanoma Therapy Premium Dec 15, 2016 Biocartis Gets CE Mark for Idylla NRAS-BRAF Mutation Test Sep 6, 2016 Combined PNA Clamp, Sensor PCR Method Shows Promise for Detection of BRAF Mutations Premium Load More Breaking News People in the News at Pacific Biosciences, Metabolon, NeoGenomics, More New Products Posted to GenomeWeb: Tethis, Invitae, PerkinElmer, More In Brief This Week: Thermo Fisher Scientific, Bruker, Quantum-Si, BioMérieux, More Luminex Obtains CE Marking for MDx Panel to Detect Flu A/B, RSV, COVID-19 Palmetto Finalizes Positive LCD for Prostate Cancer Risk Tests Gene Expression, Histology Reveal Clues for Targeted Rheumatoid Arthritis Treatment The Scan Call for a Different Tack Experts weigh the value of recent experiments testing genetically modified pig kidneys using brain-dead individuals, according to Nature News. Wastewater Warning The New York Times reports that wastewater surveillance in some parts of the US point to a possible surge. Can't Get in the Program Due to the Northern Ireland protocol dispute, the European Union is preventing UK researchers from joining the Horizon Europe research program, the Times of London reports. Science Paper on Spatial-Controlled Genome Editing In Science this week: approach to enable a CRISPR-Cas13a-based system to be used as a cancer therapy.